Serum CA19-9 Level Associated with Metabolic Control and Pancreatic Beta Cell Function in Diabetic Patients
Table 1
Demographic and clinical characteristics of study subjects.
Variables
Control ()
T1DM ()
T2DM ()
value
Gender (M/F)
64/58
34/37
507/359
—
Age (y)
*##
**
<0.001
Duration (y)
—
5.00 (1.00–8.00)##
8.00 (3.88–13.00)
0.008
ALT (U/L)
18.2 (13.00–26.75)
17.00 (11.00–27.50)
18.0 (13.00–29.00)
0.722
AST (U/L)
21.0 (17.00–25.00)
18.00 (15.00–25.00)
19.0 (15.00–24.00)
0.332
TC (mmol/L)
0.401
TG (mmol/L)
1.20 (0.87–1.79)
0.90 (0.71–1.33)*##
1.52 (1.06–2.20)**
<0.001
HDL (mmol/L)
##
**
<0.001
LDL (mmol/L)
0.256
BUN (mmol/L)
**
**
<0.001
Cr (μmol/L)
67.00 (58.00–78.00)
65.50 (51.25–79.75)
66.00 (54.00–80.00)
0.855
FPG (mmol/L)
**##
**
<0.001
2hPG (mmol/L)
**
**
<0.001
HbA1c (%)
**
**
<0.001
GA (%)
—
##
0.001
CP0 (ng/mL)
6.84 (5.08–9.85)
0.25 (0.05–0.80)**##
1.62 (1.04–2.31)**
<0.001
CP120 (ng/mL)
36.80 (22.44–57.97)
0.40 (0.48–1.42)**
3.37 (2.05–5.29)**
<0.001
CP (ng/mL)
28.84 (16.43–52.42)
0.08 (0.00–0.62)**##
1.59 (0.77–2.77)**
<0.001
CA19-9 (KU/L)
4.69 (2.66–9.65)
18.59 (11.68–39.28)**##
12.07 (6.72–21.57)**
<0.001
Data represent means ± S.D. or median (interquartile range), *, ** versus control group; #, ## versus T2DM group. ALT, aspartate aminotransferase; AST, alanine aminotransferase; BUN, blood urea nitrogen; Cr, creatinine; FPG, fasting plasma glucose; 2hPG, 2h plasma glucose; HbA1c, glycated hemoglobin A1C; GA, glycated serum albumin; TG, total triglycerides; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CP0, C Peptide of 0 min; CP120, C Peptide of 120 min; CP, D value of C Peptide of 120 min minus C Peptide of 0 min.